Efficacy of aflibercept in vitrectomized vs. non-vitrectomized eyes with diabetic macular edema: a prospective study
Abstract Background Diabetic macular edema (DME) is a leading cause of visual impairment in patients with diabetes. Intravitreal anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for DME, with aflibercept having demonstrated favorable outcomes in comparative studies....
I tiakina i:
| Ngā kaituhi matua: | , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2025-12-01
|
| Rangatū: | International Journal of Retina and Vitreous |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s40942-025-00778-y |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|